Clinical Trial: 20298

Trial Status: Open
Disease Type: Gynecologic
Trial ID 20298
Sponsor ID

Phase 2 Study of VS-6766 (Dual RAK/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Principal Investigator
Mitul Gandhi, MD
5 Locations

Locations

Fairfax Office

Gainesville Office

Arlington Office

Loudoun Office

Alexandria Office

Learn More About This Trial
Other Relevant Trials
Trial ID DK210 (EGFR)
Sponsor ID DEKA Biosciences

Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy

Trial ID 21457
Sponsor ID Artistry-7

(ALKS 4230-007/GOG-3063) A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

Principal Investigator
Robert L. Marsh, MD
5 Locations